Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences
暂无分享,去创建一个
L. Vatten | L. Akslen | O. Haugen | J. Bjørngaard | A. Bofin | M. Engstrøm | S. Opdahl | A. Hagen | A. I. Hagen | B. Ytterhus | Marit Valla
[1] R. Gelber,et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Kevin A. Henry,et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.
[3] L. Vatten,et al. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women , 2014, International journal of cancer.
[4] C. Perou,et al. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. , 2014, The oncologist.
[5] L. Vatten,et al. Modern mammography screening and breast cancer mortality: population study , 2014, BMJ : British Medical Journal.
[6] L. Vatten,et al. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women , 2014, Cancer Causes & Control.
[7] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[8] V. Speirs,et al. The value of archival tissue blocks in understanding breast cancer biology , 2013, Journal of Clinical Pathology.
[9] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] L. Vatten,et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients , 2013, Breast Cancer Research and Treatment.
[11] B. Møller,et al. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program , 2013, Cancer.
[12] C. Ambrosone,et al. Time-trends in survival in young women with breast cancer in a SEER population-based study , 2013, Breast Cancer Research and Treatment.
[13] M. Rinaldo,et al. Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series , 2013, BMC Cancer.
[14] S. Hofvind,et al. Breast cancer incidence trends in Norway—explained by hormone therapy or mammographic screening? , 2012, International journal of cancer.
[15] L. Vatten,et al. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use , 2012, BMJ : British Medical Journal.
[16] Jack Cuzick,et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.
[17] M. Kumle,et al. Mammography activity in Norway 1983 to 2008 , 2011, Acta oncologica.
[18] Philippe Autier,et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database , 2011, BMJ : British Medical Journal.
[19] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] F M Blows,et al. Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer , 2011, British Journal of Cancer.
[21] L. Bernstein,et al. Menopausal Hormone Therapy and Subsequent Risk of Specific Invasive Breast Cancer Subtypes in the California Teachers Study , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[22] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[23] Päivi Heikkilä,et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.
[24] S. Duffy,et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival , 2009, British Journal of Cancer.
[25] A. Auvinen,et al. HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 , 2009, Breast Cancer Research.
[26] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[27] P. Porter,et al. Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer , 2009, Cancer.
[28] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] V. Kataja,et al. Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening , 2008, Clinical Cancer Research.
[30] C. Perou,et al. Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.
[31] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Robert N Hoover,et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.
[33] Bingshu E. Chen,et al. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] F. Berrino,et al. Time trends of breast cancer survival in Europe in relation to incidence and mortality , 2006, International journal of cancer.
[35] T. Stijnen,et al. Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.
[36] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[37] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[38] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[39] W. Foulkes,et al. A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors , 2005, Cancer Epidemiology Biomarkers & Prevention.
[40] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[42] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[44] E. Vittinghoff,et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.
[45] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[46] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[47] R. Peto,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.
[48] Ivar Heuch,et al. A prospective study of reproductive factors and breast cancer. II. Age at first and last birth. , 1987, American journal of epidemiology.
[49] Ivar Heuch,et al. A prospective study of reproductive factors and breast cancer. I. Parity. , 1987, American journal of epidemiology.
[50] K. Gelmon,et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Sunil R. Lakhani,et al. WHO classification of tumours of the breast , 2012 .
[52] G. Colditz,et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer , 2011, Breast Cancer Research and Treatment.
[53] B. Møller,et al. Cancer incidence, mortality, survival and prevalence in Norway , 2011 .
[54] Arnulf Langhammer,et al. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation , 2003 .
[55] K. Malone,et al. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] R. Elledge,et al. Rising levels of estrogen receptor in breast cancer over 2 decades. , 1994, Cancer.
[57] Jack Cuzick,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .